

Novacyt S.A.
 ("Novacyt", the "Company" or the "Group")

Publication of Annual Report

Paris, France, and Manchester, UK - 11 June 2026- Novacyt S.A. (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international molecular diagnostics company with a broad portfolio of integrated technologies and services, announces that the Company's Annual Report and Accounts ("Annual Report") for the year ended 31 December 2025 has been published and uploaded to the Company's website.

Contacts

Novacyt SA

Lyn Rees, Chief Executive Officer
 Steve Gibson, Chief Financial Officer

<https://novacyt.com/investors>

Via Walbrook PR

SP Angel Corporate Finance LLP (Nominated Adviser and Broker)

+44 (0)20 3470 0470

Matthew Johnson / Charlie Bouverat (Corporate Finance)
 Vadim Alexandre / Rob Rees (Corporate Broking)

Singer Capital Markets (Joint Broker)

+44 (0) 20 7496 3000

Phil Davies / James Fischer / Samed Ethem

Allegra Finance (French Listing Sponsor)

+33 (1) 42 22 10 10

Rémi Durgetto / Yannick Petit

r.durgetto@allegrafinance.com / y.petit@allegrafinance.com

Walbrook PR (Financial PR & IR)

+44 (0)20 7933 8780 or novacyt@walbrookpr.com

Paul McManus / Lianne Applegarth
 Alice Woodings

+44 (0)7980 541 893 / +44 (0)7584 391 303

+44 (0)7407 804 654



PRIMER
 DESIGN

Yourgene
 Health

SCD
 SOUTHERN CROSS
 DIAGNOSTICS

About Novacyt Group (www.novacyt.com)

Novacyt is an international molecular diagnostics company providing a broad portfolio of integrated technologies and services, primarily focused on the delivery of genomic medicine. The Company develops, manufactures, and commercialises a range of molecular assays and instrumentation to deliver workflows and services that enable seamless end-to-end solutions from sample to result across multiple sectors including human health, animal health and environmental.

The Company is divided into three business segments:

Clinical

Broad portfolio of human clinical *in vitro* diagnostic products, workflows and services focused on three therapeutic areas:

- Reproductive Health: NIPT, Cystic Fibrosis and other rapid aneuploidy tests
- Precision Medicine: DPYD genotyping assay
- Infectious Diseases: Winterplex, multiplex winter respiratory PCR panel

Instrumentation

Portfolio of next generation size selection DNA sample preparation platforms and rapid PCR machines, including:

- Ranger® Technology: automated DNA sample preparation and target enrichment technology
- genesig q16 and q32 real-time quantitative PCR (qPCR) instruments

Research Use Only

Range of services for the life sciences industry:

- Design, manufacture, and supply of high-performance qPCR assays and workflows for use in human health, agriculture, veterinary and

instruments for use in human health, agriculture, forestry and environmental, to support global health organisations and the research industry

- Pharmaceutical research services: whole genome sequencing (WGS) / whole exome sequencing (WES)

Novacyt is headquartered in Le Vésinet in France with offices in the UK (Manchester), Singapore, the US and Canada and has a commercial presence in over 65 countries, including Australia, following the recent acquisition of Southern Cross Diagnostics in March 2026, which has opened new distribution channels to the life sciences and diagnostics industries in the territory and the wider Asia-Pacific region.

The Company is listed on the London Stock Exchange's AIM market ("NCYT") and on the Paris Stock Exchange Euronext Growth ("ALNOV").

For more information, please refer to the website: www.novacyt.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact ms@seg.com or visit www.ms.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

MSCURAURNVUNAAR